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Healthcare industry participants – whether biotech,
diagnostic, medical device or classical pharmaceuticals –
depend in large part on successfully collaborating with
academic institutions as a source of innovation and
clinically-relevant new products. Historically this has
most often been in the form of pure licensing arrange-
ments, whereby new inventions and discoveries are
licensed by the manufacturer for their internal further
development and eventual marketing, and royalty pay-
ments accrue to the institution. In this model, the ‘dis-
covery’ is the providence of the academic researcher,
and the risk and cost of development is borne by the
manufacturer.
Increasingly, however, collaborative partnerships are
forming between industry and academia that encompass
a broader scope, longer duration, and involve greater
risk sharing. A major driver of these collaborative activ-
ities is the increasing recognition that translational med-
icine – linking discovery with clinical application – is a
means for both the industrial and academic partner to
reduce their respective risks, quickly demonstrate new
product safety and efficacy and more rapidly bring new
treatment and diagnostic modalities to market.
Prime examples of this new paradigm are now being
created in the areas of cell therapy and personalized
medicine, particularly companion diagnostics. In this
talk, we will discuss these examples, the new model that
is developing, and how both academic institutions and
industry can form successful partnerships.
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